narsoplimab

BIOLOGICAL2 trials

Sponsors

Omeros Corporation, QuantumLeap Healthcare Collaborative

Conditions

COVID-19Hematopoietic Stem Cell Transplant Associated Thrombotic Microangiopathy (HSCT-TMA)

Phase 2

I-SPY COVID-19 TRIAL: An Adaptive Platform Trial for Critically Ill Patients

Active, not recruitingNCT04488081

QuantumLeap Healthcare CollaborativeCOVID-19

Start: 2020-07-31End: 2030-07-31Target: 1500Updated: 2026-03-16

Unknown Phase

Single Patient Expanded Access Treatment Plan For The Investigational Product Narsoplimab

Omeros CorporationHematopoietic Stem Cell Transplant Associated Thrombotic Microangiopathy (HSCT-TMA)

Updated: 2026-03-05

Related Papers

Simulation-Based Bayesian Predictive Probability of Success for Interim Monitoring of Clinical Trials With Competing Event Data: Two Case Studies.

2026-01-011 citations

Survival in adults with high-risk TA-TMA: a comparative analysis of narsoplimab vs supportive care.

2026-01-011 citations

Systematic data capture reduces the need for source data verification: exploratory analysis from a phase 2 multicenter randomized controlled platform trial.

2025-10-29

Anti-CD14 Treatment in Patients With Severe COVID-19 Clinical and Biological Effects in a Phase 2 Randomized Open-Label Adaptive Platform Clinical Trial

CHEST Critical Care2024-12-092 citations

Phosphatidylethanol measures in patients with severe <scp>COVID</scp>‐19‐associated respiratory failure identify a subset with alcohol misuse

Alcohol Clinical and Experimental Research2024-11-26

Report of the first seven agents in the I-SPY COVID trial: a phase 2, open label, adaptive platform randomised controlled trial.

2023-03-0318 citations

I-SPY COVID adaptive platform trial for COVID-19 acute respiratory failure: rationale, design and operations

BMJ Open2022-06-0125 citations